Pricing Log in Create free account
Friday 6 November 2026 Export DRIO’s income statement to Excel — free account

DarioHealth Corp.

DRIO Healthcare Health Information Services

DarioHealth Corp.’s revenue for fiscal 2025 (year ended December 2025) was $22.4 million, down 17.3% from fiscal 2024.

Revenue
−3.58%
EPS
+76.0%
Free cash flow
−0.74%
Total debt
+1.85%

Quarter to June 2026, against a year earlier

2.43 0.30 −10.99%
Market cap
$26.7M
P/E
0.0×
Fwd P/E
−0.8×
Dividend yield
—
F-score
3/9
Altman Z
−5.72
Beneish M
−3.58
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.10
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — 1 — — — —
Sell — — — — — — — — — — — —
Insider Ownership 21.45%

Capital & Financial Ratios $m

Size
Market Cap 26.70
Revenue ttm 21.00
Net income ttm (35.67)
Free cash flow ttm (25.47)
Net debt Q 16.81
Valuation
P/E 0.00
Forward P/E (0.75) (negative: loss-making)
Price / sales 1.08
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.41
Financial health
Current ratio Q 2.31 (at or above 1.5: strong)
Debt / equity Q 0.56
Interest coverage Q (5.77)
Growth
Revenue growth Q −3.58% (below 0%: shrinking)
Operating income growth Q +29.58% (above 0%: growing)
EPS, this year +60.70% (at or above 15%: strong)
EPS, next year A +36.63% (at or above 15%: strong)
Revenue, next year A −2.72% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +45.15% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.4×, against a ten-year median of 2.5×; over the ten years it ranged from −5.7× in 2016 to 23.5× in 2021.
P/S against its own 10 years 7.62%
10-year low 10-year high
P/B against its own 10 years 7.17%
10-year low 10-year high
EV/Sales against its own 10 years 42.37%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 37 29 26 14
Receivables 5 7 5 4
Inventory 5 5 4 4
Other — — — —
47 41 35 22
2023 2024 2025 Q'26
Payables 1 3 3 3
ST’ Debt 4 5 — —
Other — — — —
12 17 9 10

Compound Annual Growth %

10y 5y 3y
Sales 39.13% 24.17% (6.84%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 56.37% 19.26% (5.31%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.76 Actual −0.57

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −2.63 −1.85 Beat by 0.78
Q4 FY25 −1.57 −0.80 Beat by 0.77
Q1 FY26 −0.71 −0.81 Miss by 0.10
Q2 FY26 −0.76 −0.57 Beat by 0.19
Q3 FY26 −0.51 — Reports 12 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (1.25) (0.85) — — —
’25 (2.87) (3.54) (2.96) (2.04) (10.12)
’24 (4.00) (6.83) (4.91) (2.48) (12.27)
’23 (9.30) (11.60) (9.80) (9.90) (38.60)
’22 (14.80) (14.80) (12.80) (10.20) (50.80)
’21 (18.40) (19.80) (23.60) (21.80) (81.40)
’20 (64.01) (13.60) (17.88) (21.20) (80.20)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 6 5 — — —
’25 7 5 5 5 22
’24 6 6 7 8 27
’23 7 6 4 4 20
’22 8 6 7 7 28
’21 4 5 6 6 21
’20 2 2 2 2 8
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) (6) — — —
’25 (7) (6) (7) (6) (26)
’24 (13) (11) (7) (7) (39)
’23 (5) (10) (9) (7) (30)
’22 (18) (11) (11) (8) (48)
’21 (11) (12) (12) (15) (50)
’20 (5) (3) (4) (7) (18)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (6) (6) — — —
’25 (7) (6) (7) (6) (26)
’24 (13) (11) (7) (7) (39)
’23 (5) (10) (9) (7) (31)
’22 (18) (11) (11) (8) (48)
’21 (11) (12) (13) (15) (51)
’20 (5) (3) (4) (7) (18)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.4
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 3 5 7 8 8 21 28 20 27 22 21 +26.0% 22 29 41 +22.2%
Gross margin, % (29.61) 25.36 23.87 34.36 33.17 19.32 34.91 29.40 49.06 56.64 58.15 +86.3 pt
EBT (11) (16) (18) (18) (29) (77) (62) (59) (45) (42) (35) +16.1%
EBT margin, % (388.41) (304.51) (240.78) (234.63) (388.66) (374.05) (224.87) (291.68) (164.94) (186.10) (167.64) +202.3 pt
Net income (11) (16) (18) (18) (29) (77) (62) (59) (43) (42) (36) +16.1%
Per share, $
Per share, $ Revenue 215.62 214.52 126.18 66.72 25.41 24.73 23.40 14.35 11.03 5.61 2.25 (33.3%)
Earnings (836.00) (656.00) (312.00) (160.00) (80.20) (81.40) (50.80) (38.60) (12.27) (10.12) (7.10) (38.8%)
Cash flow (644.54) (440.62) (195.73) (138.79) (59.48) (60.76) (40.48) (21.41) (15.73) (6.51) (2.71) (40.0%)
Capex (62.15) (8.09) (1.21) (0.86) (0.40) (0.31) (0.48) (0.41) (0.06) (0.04) (0.01) (56.4%)
Free cash flow (706.69) (448.71) (196.95) (139.66) (59.87) (61.08) (40.97) (21.83) (15.78) (6.55) (2.73) (40.6%)
Book value (503.15) 163.53 152.30 166.76 94.40 103.12 67.69 40.99 29.37 17.05 5.90 n/m
Shares, m 0 0 0 0 0 1 1 1 2 4 6 +88.9%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 5.86 3.00 2.46 1.97 11.25 10.49 3.72 2.36 1.43 2.03 1.08 4.5
P/B 0.00 3.94 2.04 0.79 3.03 2.52 1.29 0.82 0.54 0.67 0.41 1.6
EV/Sales 5.39 2.23 0.95 (0.65) 7.52 8.75 2.90 1.94 1.44 2.69 2.37 3.3
EV/FCF (1.65) (1.03) (0.61) 0.31 (3.19) (3.54) (1.65) (1.26) (0.99) (2.27) (1.93) (1.6)
Cash, $m
Cash, $m Operating cash flow (8) (11) (11) (16) (18) (50) (48) (30) (39) (26) (25) +13.4%
Capex (1) 0 0 0 0 0 (1) (1) 0 0 0 (17.6%)
Free cash flow (9) (11) (12) (16) (18) (51) (48) (31) (39) (26) (25) +12.3%
Balance, $m
Balance, $m Working capital 0 3 8 18 27 31 46 35 24 26 13 +136.8%
Net debt (1) (4) (11) (20) (28) (36) (23) (9) 0 5 17 n/m
Shareholders’ equity (7) 4 9 19 28 86 80 58 72 68 55 n/m
Returns, %
Returns, % ROA (259.40) (295.47) (173.87) (108.08) (110.39) (115.68) (58.04) (58.92) (38.07) (53.93) (44.19) +205.5 pt
ROIC 0.00 0.00 0.00 0.00 0.00 (95.93) (61.85) (70.80) (49.91) (31.63) (27.67) (31.6) pt
ROE 285.85 1,230.62 (284.41) (150.19) (140.73) (138.55) (77.12) (91.95) (62.97) (88.23) (76.05) (374.1) pt
People
People Employees 31 48 76 72 139 214 252 294 202 165 — +20.4%
Revenue/emp, $m 0.09 0.11 0.10 0.10 0.05 0.10 0.11 0.07 0.13 0.14 — +4.6%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

DarioHealth Corp. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HCAT Health Catalyst, Inc. $112.9M — (loss-making) — (loss-making) −26.26% (below 0%: shrinking) n/m +65.58% (above 0%: growing) 42.71% 89.08% Compare
LFMD LifeMD, Inc. $110.4M — (loss-making) — (loss-making) −3.55% (below 0%: shrinking) n/m −247.52% (below 0%: shrinking) 88.82% (15.08%) Compare
CCLD CareCloud, Inc. $91.8M 16.5× 11.0× +8.56% (above 0%: growing) +150.00% (above 0%: growing) −0.44% (below 0%: shrinking) 50.46% 19.50% Compare
DRIO DarioHealth Corp. $26.7M — (loss-making) — (loss-making) −3.58% (below 0%: shrinking) n/m −0.74% (below 0%: shrinking) 61.66% (125.15%)
ONMD OneMedNet Corporation $25.1M — (loss-making) — +88.39% (above 0%: growing) n/m +14.05% (above 0%: growing) (193.49%) (774.32%) Compare
BEAT HeartBeam, Inc. $22.2M — (loss-making) — — n/m −1.24% (below 0%: shrinking) — 0.00% Compare
RNLXY Renalytix plc - Sponsored ADR $17.2M — (loss-making) — +13.73% (above 0%: growing) n/m +17.96% (above 0%: growing) 19.16% (783.91%) Compare
BFRG Bullfrog AI Holdings Inc. $9.1M — (loss-making) — (loss-making) +2,054.00% (above 0%: growing) n/m −5.67% (below 0%: shrinking) 49.63% (658.82%) Compare
HLTHQ Cue Health Inc. $6.9M — (loss-making) — (loss-making) −87.19% (below 0%: shrinking) n/m +50.55% (above 0%: growing) (90.14%) (792.13%) Compare
Median of peers $23.7M — — +8.56% — +6.81% 42.71% (336.95%)

All 44 Health Information Services stocks →

Pay and ownership Proxy statement filed 22 December 2025

Chief executive’s pay

Year Total pay Actually paid $100 invested
2024 1.96m 1.68m 45.70
2023 722.19k 274.28k 40.13

Ownership

Directors and executive officers, together 3.50%
Nantahala Capital Management LLC 9.90%
Tasso Partners, LLC 9.90%
Craig Kallman 9.90%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

DarioHealth Corp. (DRIO) Latest News

29 Oct

Impact 3 · · Simply Wall St.

26 Oct

Impact 4 · · PR Newswire

6 Oct

Impact 4 · · PR Newswire

17 Sep

Impact 4 ·

11 Aug

Impact 4 · transcript
Impact 3 · · The Motley Fool transcript
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat transcript
Impact 3 ·

4 Aug

Impact 3 ·

30 Jul

Impact 4 ·

16 Jul

Impact 4 · · Stocktwits
Impact 4 ·

13 Jul

Impact 4 ·

6 Jul

Impact 4 ·

2 Jul

Impact 4 ·

29 Jun

Impact 4 ·

17 Jun

Impact 3 ·

8 Jun

Impact 3 · · PR Newswire

26 May

Impact 4 · · PR Newswire

14 May

Impact 3 · · Moby transcript

13 May

Impact 4 · · GuruFocus.com
Impact 4 · · MarketBeat
Impact 4 · · Benzinga transcript
Impact 4 · · PR Newswire
Impact 3 · · Zacks

29 Apr

Impact 4 ·

20 Apr

Impact 3 ·

13 Apr

Impact 3 · · PR Newswire

24 Mar

Impact 4 · · Simply Wall St.
stockrow.com/DRIO · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com